Menu

TS Picks: October 24, 2016

Theranos’s bad blood tests; presidential science lessons; “three-parent” babies

Oct 24, 2016
Tracy Vence

PUBLIC DOMAIN PICTURES, CIRCE DENYER

Selections from The Scientist’s reading list

  • The Wall Street Journal spoke with patients who were affected by inaccurate Theranos blood tests. “Rattled patients who told The Wall Street Journal they sought more information about their results said they got no response, and weeks or months passed before Theranos told many patients that their results were unreliable.” The Wall Street Journal also reviewed an undisclosed report from the US Centers for Medicare and Medicaid Services, which found that 834 of 2,890 quality-control checks using the company’s proprietary Edison devices “exceeded the company’s threshold of two standard deviations from its average result,” the publication reported.

See “Theranos Restructuring with Research Focus

See “Theranos CEO Banned from Running Labs for Two Years

  • Science last week (October 20) offered “science lessons for the next president,” including backgrounders on evolving pathogens and applications of CRISPR.
     
  • Last month, New Scientist reported on the birth of the first baby to have been treated with mitochondrial replacement therapy (MRT). Now, “that ‘three-parent’ baby may soon have company—if it does not already,” Nature reported last week (October 29). “Numerous scientific groups and government agencies are debating whether the procedure should be allowed in clinical use. Most conclude that mitochondrial replacement should be performed only under the auspices of a clinical trial and with independent oversight.”

See “First MRT Baby Born

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.
Corning Introduces New 1536-well Spheroid Microplate
Corning Introduces New 1536-well Spheroid Microplate
High-throughput spheroid microplate benefits cancer research, drug screening